Strata’s Earnings Call: Acquisition Timing, Margin Outlook, and Growth Signals Don’t Match

Date of Call: Aug 4, 2026

Financials Results

• Revenue: $72.5M, up 60.7% YOY; clinical revenue up 23.8% organically, logistics revenue up 6.9% YOY
• Gross Margin: Overall gross margin 21%, up 100 basis points YOY; clinical gross margin 26.1%, up from 25% in Q1; logistics gross margin 18.4%, down from 19.3% prior quarter

Guidance:

• Increased 2026 revenue guidance to $285-$295M from $260-$267M.
• Increased 2026 adjusted EBITDA guidance to $33-$35M from $29-$33M.
• Logistics revenue expected to decrease high single digits sequentially in Q3, then recover to near Q2 levels by Q4.
• Logistics gross margin expected to improve to 18.5%-20% range in second half, targeting 20% in 2027.
• Clinical revenue expected to grow ~20% sequentially in Q3, with gross margin increasing to 27%-28% range in second half.
• Free cash flow expected to build into year-end, with Joby earn-out of $17.5M anticipated by year-end.

Business Commentary:

Strong Clinical Business Growth:

• Strava reported that its clinical revenue increased 23.8% sequentially in Q2 2026, contributing to an overall 15.1% increase in clinical revenue.
• This growth was driven by the acquisition of new clinical businesses and the expansion of existing services.

Cash Flow Generation:

• The company generated $5.7 million of operating cash flow and $2.9 million of free cash flow in Q2 2026, marking the second consecutive quarter of cash generation.
• This was supported by increased operational efficiency and strategic capital deployment.

Logistics Revenue Challenges:

• Logistics revenue experienced a 6.9% year-over-year increase, but a 3% headwind was noted due to reduced flying levels from a specific customer.
• The reduction in flying was attributed to unique circumstances related to one customer's transplant program.

Strategic Acquisitions:

• Strava completed three bolt-on acquisitions in Q2 2026, adding $6 million in revenue and enhancing its clinical service offerings.
• These acquisitions were strategic, aimed at strengthening competitive positioning and expanding geographic reach.

Gross Margin Improvement in Clinical Segment:

• Clinical gross margin increased to 26.1% in Q2 2026 from 25% in Q1 2026.
• The improvement was due to the positive mix impact from the addition of clinical businesses and acquisitions.

Sentiment Analysis:

Overall Tone: Positive

• Management highlighted 'strong results,' 'accelerating growth in our clinical business,' 'increased cash flow generation,' and being 'well ahead of schedule' on M&A. They noted 'the best is yet to come' and are 'excited about the growth potential,' despite some short-term logistics headwinds which they are 'proactive' in addressing.

Q&A:

• Question from Yuan Zhig (B. Reilly): Excluding recent acquisitions, can you detail logistics industry volume trends?
  Response: Management pointed to sequential growth in clinical business and gaining market share, supported by industry data showing a sequential step-up in NRP usage, indicating overall DCD donor volume is recovering.

• Question from Yuan Zhig (B. Reilly): Can you expand on dry round rates and which organs have the highest?
  Response: Dry run risk is evaluated donor-specifically; the company's integrated service offering allows customers to attempt more donors by reducing risk, as surgeons can be deployed locally without turning on an airplane until acceptance is known.

• Question from Ben Haynor (Lake Street Capital Markets): What drove Q2 outperformance and the general outlook?
  Response: Outperformance was driven by both organic base business growth and acquisitions; the increased guidance reflects contributions from acquisitions and underlying business outperformance.

• Question from Ben Haynor (Lake Street Capital Markets): What specific actions are being taken to restore logistics gross margin to 20%?
  Response: Actions include removing low-margin operators/airplanes, replacing with more efficient dedicated operators, and reallocating hours to better-performing providers to amortize fixed costs.

• Question from Ben Haynor (Lake Street Capital Markets): Does the cardiac perfusion acquisition help identify new targets?
  Response: Yes, the acquired teams are actively helping identify new clinical acquisition targets, as their story is compelling for growth, efficiency, and expanding geographic reach.

Contradiction Point 1

Industry DCD Donor Volume Trend

Contradiction on sequential growth trend for DCD donors.

Yuan Zhig (B. Reilly) - Yuan Zhig (B. Reilly)

2026Q2: Industry DCD donor volume showed low single-digit sequential growth in Q2 2026 versus Q1 2026... - [Will Haber](CFO)

What's the industry's DCD donor volume trend in recent quarters, excluding acquisitions? - William Bonello (Craig-Hallum Capital Group LLC)

2026Q1: The initial step-up after the Keystone acquisition has been captured, so no big step-up is expected again... - [William Heyburn](CFO)

Contradiction Point 2

Logistics Revenue Mix Disclosure

Contradiction on providing a breakdown of air vs. ground revenue.

Ben Haynor (Lake Street Capital Markets) - Ben Haynor (Lake Street Capital Markets)

2026Q2: The company provides this disclosure in its investor presentation, where you can break out the approximate ground revenue... - [Matt Schneider](CFO)

Can you break down the logistics revenue by air and ground? - William Bonello (Craig-Hallum Capital Group LLC)

2026Q1: The shift in Logistics mix to OPOs is also considered normal quarter-to-quarter variability. - [Mathew Schneider](CFO)

Contradiction Point 3

Logistics Gross Margin Outlook

Contradiction on the timeline for achieving a 20% logistics gross margin target.

Ben Haynor (Lake Street Capital Markets) - Ben Haynor (Lake Street Capital Markets)

2026Q2: The initiatives are expected to show results, with logistics gross margin returning to the 20% target in 2027, though some quarterly volatility is inherent to the business. - [Will Haber](CFO)

What specific actions are being taken to restore logistics gross margin to the 20% target, and how long will the effects last? - Jon Hickman (Ladenburg Thalmann)

2025Q4: The asset-light network allows flexibility, as dedicated aircraft can be moved. Bases indicate a certain aircraft availability, but the network is dynamic. - [Mathew Schneider](CFO of Clinical Services & VP of Finance and Investor Relations)

Contradiction Point 4

Acquisition Contribution Timing

Contradiction on whether acquisition contributions are included in the current quarter's performance or outlook.

Ben Haynor (Lake Street Capital Markets) - Ben Haynor (Lake Street Capital Markets)

2026Q2: The increased guidance is driven by two factors: 1) Contributions from acquisitions completed in Q2 2026, and 2) Outperformance in the base business. - [Will Haber](CFO)

What factors contributed to Q2 outperformance and the overall annual outlook? - Benjamin Haynor (Lake Street Capital Markets)

2025Q4: Acquisitions in the core business will be announced as they close. The pipeline is robust, and the company is being approached by small competitors seeking scale and regulatory compliance. - [Melissa Tomkiel](CCO) & [William Heyburn](CFO)

Contradiction Point 5

Growth Drivers and Guidance

Guidance attributed to acquisitions versus organic growth contradicts prior emphasis on broad growth drivers.

Ben Haynor (Lake Street Capital Markets) - Ben Haynor (Lake Street Capital Markets)

2026Q2: The increased guidance is driven by two factors: 1) Contributions from acquisitions completed in Q2 2026, and 2) Outperformance in the base business. - [Will Haber](CFO)

What drove Q2's outperformance and the year's outlook? - Benjamin Haynor (Lake Street Capital Markets)

2025Q3: Growth was driven by a mix of new customer acquisition, market share gains from existing customers, and upsell of new services to existing customers. ... Yes, the company expects to continue adding new customers, consolidate market share in a fragmented industry... - [William Heyburn](CEO)